---
type: "Article"
title: "ADC Analysis: key questions & answers from FILAB Laboratory"
description: "Antibody-Drug Conjugates (ADCs) are revolutionizing targeted therapies. By combining the specificity of a monoclonal antibody with the potency of a cytotoxic drug, they offer highly targeted treatments. However, this hybrid nature makes ADC analysis exceptionally complex. To help biopharmaceutical companies..."
resource: "https://filab.fr/en/blog/2026/02/adc-analysis-services-expert-qa-filab-laboratory/"
tags: ["Analytical Techniques", "Chemical Analysis", "EN"]
timestamp: "2026-02-27T08:22:23Z"
published: "2026-02-24T13:15:52Z"
language: "en"
author: "Filab"
---

# ADC Analysis: key questions & answers from FILAB Laboratory

[Antibody-Drug Conjugates (ADCs)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/adc-sequencing-services-laboratory-antibody-drug-conjugate.md) are revolutionizing targeted therapies. By combining the specificity of a monoclonal antibody with the potency of a cytotoxic drug, they offer highly targeted treatments. However, this hybrid nature makes **ADC analysis** exceptionally complex. To help biopharmaceutical companies navigate these analytical challenges, the experts at **FILAB**Laboratory answer your key questions.

## ADC Analysis: key questions & answers

### What makes ADC characterization more complex than traditional biologics?

Unlike standard [monoclonal antibodies (mAbs)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-monoclonal-antibodies-mabs.md), ADCs consist of three distinct components: **the antibody, the linker, and the cytotoxic payload.**

This structural complexity creates high heterogeneity. Analytical methods must not only characterize the intact protein but also assess the small-molecule drug, the stability of the linker, and the distribution of the drug molecules on the antibody.

Standard [biopharmaceutical testing](https://filab.fr/en/sectors-of-activity/biopharmaceutical.md) is simply not enough; it requires specialized, multi-disciplinary analytical expertise.

At **FILAB**, we perform comprehensive structural confirmation of[ADCs](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/adc-antibody-drug-conjugates-characterization.md) combining high-resolution mass spectrometry ([HPLC-HRMS](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc.md)), peptide mapping, and orthogonal physicochemical techniques to ensure full molecular understanding.

Our approach covers primary sequence confirmation ([peptide mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md) and [de novo sequencing](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/de-novo-protein-sequencing.md)), intact mass determination, disulfide bridge characterization, and higher-order structure evaluation ([FTIR](https://filab.fr/en/our-technical-resources/laboratory-analysis-ftir-spectroscopy.md), [Circular Dichroism](https://filab.fr/en/sectors-of-activity/biopharmaceutical/measurement-circular-dichroism-cd.md), [DSC](https://filab.fr/en/our-technical-resources/laboratory-analysis-dsc-calorimetric.md)).

This multi-level strategy allows precise control of Critical Quality Attributes (CQAs) required for CMC development.

### What is the Drug-to-Antibody Ratio (DAR) ?

  Services
## Drug-to-Antibody Ratio (DAR)

 The Drug-to-Antibody Ratio (DAR) is a critical quality attribute (CQA) that directly impacts the efficacy, toxicity, and pharmacokinetics of the ADC. A DAR that is too low might result in poor therapeutic efficacy, while a DAR that is too high can lead to increased toxicity and faster clearance from the bloodstream. How we measure it? Liquid chromatography-mass spectrometry (LC-MS)
To accurately determine both the average DAR and the drug load distribution.

 HPLC-HRMS intact mass analysis
We resolve the different DAR species and accurately determine the average DAR value.

 Complementary chromatographic profiling (SEC, IEX)
Allows evaluation of heterogeneity associated with conjugation.

 SEC coupled with triple detection (LALS-RALS/UV/RI)
Provides absolute molecular weight determination and aggregation monitoring, strengthening DAR interpretation.

### How do you evaluate ADC heterogeneity?

ADC conjugation introduces structural variants that must be precisely characterized. **FILAB** provides in-depth heterogeneity profiling including:

Aggregation analysis by Size Exclusion Chromatography ([SEC](https://filab.fr/en/our-technical-resources/laboratory-analysis-gpc-sec.md))

Post-Translational Modifications (PTMs) identification and quantification by [HPLC-HRMS/MS](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc.md) (deamidation, oxidation, glycosylation)...

Charge variants profiling by Ion Exchange Chromatography ([IEX-UV](https://filab.fr/en/our-services/our-analysis-services/polymer-materials-analysis-laboratory/laboratory-material-testing/rheological-analysis-laboratory-polymer-rheology/ion-chromatography-analysis-laboratory/))

Fragment characterization (HC, LC, Fab, Fc forms)

We also characterize glycosylation patterns, including carbohydrate structure elucidation, monosaccharide composition, and glycosylation site identification. This detailed profiling ensures product consistency and comparability during development.

 

### How do you assess ADC stability?

ADCs are sensitive to thermal, chemical, and oxidative stress, which may induce aggregation, fragmentation, deconjugation, or structural modification. At **FILAB**, we implement stability-indicating methods including:

  [### SEC

for aggregate and fragment quantification](https://filab.fr/en/our-technical-resources/laboratory-analysis-gpc-sec.md) [### IEX

for charge variant monitoring](https://filab.fr/en/our-services/our-analysis-services/polymer-materials-analysis-laboratory/laboratory-material-testing/rheological-analysis-laboratory-polymer-rheology/ion-chromatography-analysis-laboratory/) [### HPLC-HRMS

for structural modification detection](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc.md) [### DSC

for thermal stability assessment](https://filab.fr/en/our-technical-resources/laboratory-analysis-dsc-calorimetric.md) [### FTIR and Circular Dichroism

for higher-order structure monitoring](https://filab.fr/en/our-technical-resources/laboratory-analysis-ftir-spectroscopy.md)
Forced degradation studies (thermal, oxidative, pH stress) are performed to identify degradation pathways and evaluate linker robustness. We also quantify potential released payload and small-molecule related impurities using dedicated LC-MS methods.

 

### What impurities and contaminants must be monitored in ADCs?

ADC manufacturing introduces both biologic and small-molecule related impurities. **FILAB** supports impurity profiling including:

  services
## Process-related impurities:

**[Host Cell Proteins (HCP)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/host-cell-protein-hcp-testing-analysis-laboratory.md)** detection and quantification

Residual DNA analysis

Elemental impurities (**[ICH Q3D](https://filab.fr/en/our-services/our-analysis-services/analysis-ich-q3d-context.md)** / USP <233>) by **[ICP](https://filab.fr/en/our-technical-resources/icp-ms-analysis-laboratory.md)**

**[Extractables & Leachables (E&L)](https://filab.fr/en/our-services/our-expertise-services/laboratory-extractable-leachable-testing.md)** studies

Residual solvents and culture media components (amino acids, vitamins, saccharides)

   services
## Product-related impurities:

Aggregates

Fragments

Oxidized or deamidated forms

Free payload traces

This dual expertise in biologics and small molecules is essential for ADC quality control.

### Why choose FILAB Laboratory for your ADC analytical outsourcing?

Developing an ADC requires an agile, highly equipped, and experienced analytical partner. **FILAB** Laboratory offers:

- **State-of-the-art equipment:** High-resolution [LC-MS](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc/laboratory-analysis-hplc-lcms.md), [SEC](https://filab.fr/en/our-technical-resources/laboratory-analysis-gpc-sec.md)-HPLC, and CE systems.
- **Custom method development:** We design and validate analytical methods tailored to your specific linker-payload technology.
- **Cross-functional expertise:** Bridging the gap between large molecule characterization and small molecule impurity analysis.
- Full **physico-chemical characterization** packages adapted to CMC requirements.
- **Stability-indicating** method development and validation according to ICH guidelines.
- Support for **batch comparability studies** and process optimization.
- **GMP-compliant** analytical environment for regulated studies.

**Ready to advance your ADC development?** Do not let analytical bottlenecks slow down your pipeline.[Contact FILAB](https://filab.fr/en/contact-form.md) Laboratory to discuss your analytical needs with our biopharmaceutical experts.

[Contact us](https://filab.fr/en/contact-form.md)

We are available to answer your questions

 [MEET THE TEAM](https://filab.fr/en/about-us/the-team.md)